Therapeutic Targeting of Replicative Immortality
Seminars in Cancer Biology 35 (2015) S104–S128 Contents lists available at ScienceDirect Seminars in Cancer Biology jo urnal homepage: www.elsevier.com/locate/semcancer Review Therapeutic targeting of replicative immortality a,∗ b c d e Paul Yaswen , Karen L. MacKenzie , W. Nicol Keith , Patricia Hentosh , Francis Rodier , f g h i c Jiyue Zhu , Gary L. Firestone , Ander Matheu , Amancio Carnero , Alan Bilsland , j k,1 k,1 l,1 Tabetha Sundin , Kanya Honoki , Hiromasa Fujii , Alexandros G. Georgakilas , m,1 n,o,1 p,1 q,1 Amedeo Amedei , Amr Amin , Bill Helferich , Chandra S. Boosani , r,1 s,1 t,1 u,1 Gunjan Guha , Maria Rosa Ciriolo , Sophie Chen , Sulma I. Mohammed , v,1 r,1 w,1 m,1 Asfar S. Azmi , Dipita Bhakta , Dorota Halicka , Elena Niccolai , s,1 n,o,1 x,1 p,1 Katia Aquilano , S. Salman Ashraf , Somaira Nowsheen , Xujuan Yang a Life Sciences Division, Lawrence Berkeley National Lab, Berkeley, CA, United States b Children’s Cancer Institute Australia, Kensington, New South Wales, Australia c University of Glasgow, Glasgow, United Kingdom d Old Dominion University, Norfolk, VA, United States e Universit´e de Montr´eal, Montr´eal, QC, Canada f Washington State University College of Pharmacy, Pullman, WA, United States g University of California Berkeley, Berkeley, CA, United States h Biodonostia Institute, Gipuzkoa, Spain i Instituto de Biomedicina de Sevilla, HUVR, Consejo Superior de Investigaciones Cientificas, Universdad de Sevilla, Seville, Spain j Sentara Healthcare, Norfolk, VA, United States k Nara Medical University, Kashihara,
[Show full text]